Keystone Clinic highlights blood-based cancer screening as a supplement, not a replacement

Keystone Clinic & Surgery is pointing patients to multi-cancer early detection tests as an emerging add-on to standard cancer screening in Singapore. The clinic says the blood tests may help widen early detection, but they do not replace national screening programmes or confirm a cancer diagnosis on their own.

Why it matters: - MCED testing could give patients another way to look for cancer earlier, especially when paired with routine screening and medical follow-up. - The clinic is framing the technology as a complement to established checks, not a shortcut around proven screening tests.

What happened: - Keystone Clinic & Surgery in Singapore is highlighting Multi-Cancer Early Detection tests as an emerging screening option. - The clinic says MCED testing may complement established approaches to cancer screening. - Keystone Clinic & Surgery also points patients to nationally recommended preventive services, including Healthier SG Screening for eligible patients. - CHAS subsidies support those screenings, and eligible Healthier SG enrollees can also receive additional copayment waivers. - MCED testing is separate from those national programmes and is not part of Singapore’s national cancer screening programme.

The details: - MCED tests are commonly described as liquid biopsy tests. - The tests analyze a blood sample for signals that may be associated with cancer. - Those signals can include circulating tumor DNA, cell-free DNA patterns, and other cancer-related markers in the bloodstream. - From a patient’s perspective, the process is similar to a standard blood draw. - Depending on the platform, one blood sample may be used to screen for signals linked to many cancers. - Some MCED platforms are designed to look for signals associated with 50 or more cancer types. - An MCED blood test does not confirm cancer. - A detected signal can lead to more testing, including imaging, specialist review, and sometimes a tissue biopsy. - Keystone Clinic & Surgery says MCED should be considered an additional screening option rather than a substitute for established cancer screening. - The National Cancer Centre Singapore has also said MCED tests are not a replacement for recommended screening tests such as mammograms, Pap smears, and colonoscopies. - MCED tests can produce false-positive and false-negative results. - Detection can vary by cancer type and stage. - Early tumors may release only small amounts of circulating tumor DNA into the blood. - A result needs to be read alongside a patient’s health history and other recommended screening. - A Keystone Clinic & Surgery spokesperson said MCED is an emerging technology that could shift intervention from reactive to proactive and supplement other nationally recommended screening tests.

Between the lines: - The clinic’s message reflects a broader caution: new screening tools can expand options, but they also create a risk of over-testing and unclear results. - Singapore health experts are still working out where MCED fits in real-world screening, especially for Asian populations. - NCCS has noted that much of the existing evidence comes from Western populations, where cancer patterns and genetics may differ. - That matters because test performance may not translate the same way across populations. - The National Cancer Institute in the US also treats multi-cancer detection as an area of continuing research.

What's next: - NCCS plans a clinical study involving 1,000 people at higher risk of cancer because of genetic factors or pre-cancerous conditions. - The study is planned for the second half of 2026. - Researchers will assess whether MCED tests can identify early-stage cancers and track longer-term outcomes. - Patients will likely continue to hear MCED discussed as part of broader risk-based screening conversations, not as a standalone answer. - Keystone Clinic & Surgery is encouraging patients to discuss screening with a doctor based on age, medical history, family history, lifestyle factors, symptoms, and eligibility for established programmes.

The bottom line: - MCED tests may broaden early cancer detection, but they remain an add-on tool that needs medical interpretation and follow-up.